Pfizer
Pfizer Torcetrapib Clinical Trial Failure
Estimated impact: $800M+ direct investment; $21B market cap loss
Pfizer invested $800M in torcetrapib, a cholesterol drug designed to raise HDL ("good cholesterol"). The Phase III trial was terminated early when it increased death rates by 60%. Pfizer had built an entire manufacturing facility before the trial completed, committing to production before efficacy was proven.
Decision context
Whether to invest in manufacturing capacity and commercial launch preparations before Phase III clinical trial results confirmed safety and efficacy.
Biases present in the decision
Toxic combinations
- Optimism Trap
- Blind Sprint
Reference class base rates
Across all 146 curated case studies in our library:
Lessons learned
- Optimism bias in drug development led Pfizer to build manufacturing before pivotal trial results — a classic premature commitment
- The HDL hypothesis (raising HDL is always beneficial) was never rigorously validated, yet became consensus through anchoring to epidemiological correlations
- Sunk cost in R&D made it harder to interpret ambiguous interim data objectively
Source: Barter et al., "Effects of Torcetrapib in Patients at High Risk for Coronary Events," NEJM (2007) (Academic Paper)
See what we'd flag in your next strategic memo.
Upload a strategic memo or board deck. Get the same bias audit you just saw for Pfizer, on your own high-stakes call, in under 60 seconds.
Or leave your email, we'll run a strategic memo of your choosing and send the readout within a business day.
Ready to audit your own memo right now? Create a free account →